SARMs and the regulatory reality: research-only labels do not change legal posture

Key takeaways

• No SARM has FDA approval. The most-studied SARM (MK-2866 / enobosarm) failed phase 3 in cancer cachexia (POWER trials).
• All SARMs are WADA-prohibited at all times under section S1.2 (anabolic agents), in and out of competition.
• FDA issued a 2017 consumer warning against SARMs in body-building products and has issued ongoing warning letters; the 'research only' label disclaimer is not a regulatory category.
• Several US states have placed LGD-4033 and RAD-140 under state-level Schedule III; possession may be a state-level controlled-substance offense even where federal scheduling has not advanced.
• Independent analyses of dietary supplements detected SARMs in products that did not list them on the label; supplement contamination is a real inadvertent-positive risk for tested athletes.

What SARMs actually are

Selective androgen receptor modulators (SARMs) are non-steroidal compounds designed to bind the androgen receptor with greater tissue selectivity than testosterone or anabolic-androgenic steroids. The pharmaceutical hypothesis was that SARMs could deliver muscle and bone benefits without the prostate, liver, hematocrit, and HPG-axis liabilities of full androgen-receptor agonists. Multiple compounds (MK-2866 / ostarine, LGD-4033 / ligandrol, RAD-140 / testolone, S-4 / andarine, S-23, YK-11) reached human trials. None reached FDA approval .

The compounds are sold globally through research-chemical channels with 'not for human consumption' labels. The label disclaimer is not a regulatory category. It does not authorize sale for human use, does not change FDA jurisdiction, and does not protect either vendor or buyer from enforcement.

MK-2866 (Ostarine, Enobosarm): the deepest trial record

MK-2866 is the most-studied SARM. Originally developed by GTx as enobosarm for cancer cachexia and muscle wasting, the compound advanced through phase 3 in non-small-cell lung cancer cachexia (POWER 1 and POWER 2 trials). The pivotal trials enrolled adults with stage III/IV NSCLC and randomized to enobosarm 1 mg or 3 mg daily versus placebo for 16 weeks. The co-primary endpoints (lean body mass and physical function, with physical function assessed as stair-climb power) were evaluated via a responder analysis . In the reported results the pre-specified responder co-primaries were not met overall (continuous-variable lean body mass favored enobosarm, but the stair-climb power co-primary did not reach the responder threshold), and the FDA approval pathway did not advance .

Ostarine has continued in trials for stress urinary incontinence (in postmenopausal women) and for breast cancer-related muscle loss; an active program for stress urinary incontinence in postmenopausal women has reported phase 3 data . None of these clinical programs has produced an FDA-approved enobosarm drug product as of 2026.

Trial-level safety: HPG-axis suppression was observed even at the modest 3 mg trial dose, with reductions in total testosterone, SHBG, and LH consistent with central androgen receptor activity. Mild liver enzyme elevations and reductions in HDL were reported. Body-composition use at the 10-25 mg daily doses cited by community sources is well above the trial range.

LGD-4033 (Ligandrol): phase 1 healthy-men data

LGD-4033 reached phase 1 in healthy men. Basaria and colleagues published a 2013 randomized placebo-controlled study of LGD-4033 0.1, 0.3, and 1.0 mg daily for 21 days in 76 healthy men. Lean body mass increased dose-dependently, total testosterone and SHBG dropped, and HDL declined. The trial was designed for safety and short-duration pharmacology, not for body-composition outcomes .

Subsequent academic publications described LGD-4033 hepatotoxicity case reports in users taking community doses (5-10 mg daily) for several weeks, with elevated transaminases that resolved on discontinuation in most cases . No phase 2/3 efficacy trial in any indication has been published for LGD-4033 since the original phase 1 program.

RAD-140 (Testolone): first-in-human oncology trial

RAD-140 was developed by Radius Health and reached a phase 1 first-in-human trial in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer (NCT03088527). The trial tested oral RAD-140 escalating doses for tumor response and safety. The program did not advance to phase 2/3 and the company did not seek FDA approval; the trial sponsor record is on ClinicalTrials.gov .

Outside that trial, RAD-140 has no published controlled human efficacy data for any indication. Body-composition use at the community-cited 5-20 mg daily doses is unsupported by trial evidence and outruns the only completed human study, which was an oncology safety/tolerability program in a non-overlapping population . Hepatotoxicity and aggression / mood-change case reports have been described in the academic literature.

FDA posture

The FDA issued a 2017 consumer-update warning about SARMs sold in body-building products, noting serious safety risks including liver injury, increased risk of heart attack and stroke, and life-threatening reactions. The agency has issued multiple warning letters to manufacturers selling SARM-containing products and has flagged enforcement against bulk-substance distribution . The agency has also announced regulatory action against products labeled as containing SARMs that turn out to contain mislabeled or contaminated substances.

The 'research only' or 'not for human consumption' label is not a regulatory category. It does not change FDA jurisdiction, it does not authorize sale for human use, and it does not protect a vendor or buyer if the product is sold or used as an unapproved drug. Recent FDA enforcement and DOJ prosecutions have targeted vendors despite the disclaimer language.

State-level controlled-substance scheduling

Several US states have placed SARMs on state-level controlled-substance schedules. The first wave centered on LGD-4033 and RAD-140; subsequent legislative actions in Texas, Oklahoma, and other states have extended the listing to other SARMs. State scheduling is independent of federal scheduling. As of 2026, federal scheduling under the Controlled Substances Act has been proposed multiple times (most recently the SARMs Control Act variants) but has not been enacted into federal law.

Practical effect: possession and distribution may be a state-level controlled-substance offense in some jurisdictions, even though the same activity is not a federal scheduled-substance violation. Vendors typically ship from non-listing states and warn customers in some states; that does not necessarily protect the buyer. State law is what governs possession at the buyer's address.

WADA prohibition is unconditional

Selective androgen receptor modulators are listed under section S1.2 of the WADA prohibited list and are prohibited at all times, in and out of competition . This includes ostarine, ligandrol, andarine, and any chemical analog. Many SARM-adjacent metabolic modulators (cardarine / GW-501516, stenabolic / SR9009) sit under section S4.5 (hormone and metabolic modulators) and are also prohibited.

USADA and other national anti-doping organizations regularly publish sanction notices for athletes testing positive for SARM metabolites. A meaningful fraction of SARM-positive cases trace to contaminated dietary supplements rather than intentional use; USADA and academic groups have documented surprisingly high rates of SARM contamination in over-the-counter dietary-supplement products .

Supplement contamination: the inadvertent-positive risk

Independent analyses of dietary supplements purchased on the open US market have repeatedly detected SARMs (most often LGD-4033, ostarine, and andarine) and other prohibited substances in products that did not list those compounds on the label. The contamination rates are not trivial; one widely cited study analyzed 44 SARM-labeled products and reported that fewer than half contained only the labeled SARM at the labeled dose, with multiple products containing other SARMs, anabolic steroids, or no detectable active substance .

For a tested athlete, this is a meaningful inadvertent-positive risk even when the athlete has never knowingly used a SARM. USADA's response has been to maintain an anti-doping resource center for supplement risk and to recommend Informed Sport / Informed Choice certification, but no certification scheme guarantees zero contamination.

Hepatotoxicity, lipids, and cardiovascular risk

Documented adverse-event patterns at community body-composition doses cluster across the major SARMs:

• Drug-induced liver injury: cholestatic or mixed hepatocellular hepatitis associated with LGD-4033, RAD-140, and YK-11; weeks into use; most cases resolve on discontinuation, but hospitalization-requiring cases reported .
• HDL reductions: orally dosed SARMs suppress HDL cholesterol dose-dependently. In the only randomized SARM trial reporting lipids, LGD-4033 lowered HDL by roughly 20 percent at 0.3 mg and about 40 percent at 1.0 mg daily over 21 days, all below community body-composition doses; larger reductions at body-composition doses are reported in uncontrolled case series but are not quantified in controlled trials . Clinical significance of acute HDL reductions is debated, but the suppression signal is consistent and is one component of the FDA cardiovascular concern.
• HPG-axis suppression: total testosterone, SHBG, and LH all decline at trial doses; recovery time after discontinuation is variable and not guaranteed.
• Cardiomyopathy and major cardiovascular events: case reports in long-term SARM users; causality is not established but the signal exists in the published case literature.
• Visual disturbances (S-4 / andarine): yellow / blue visual disturbances and impaired dim-light adaptation are dose-dependent and resolve on discontinuation in most user accounts.

The 'cycle' and PCT conversation, in scope

Community use of SARMs typically frames dosing as a 'cycle' (4-12 weeks on) followed by 'post-cycle therapy' (PCT) intended to recover endogenous testosterone production. PCT regimens commonly cite SERMs (clomiphene, tamoxifen) and aromatase inhibitors. None of those compounds are FDA-approved for HPG-axis recovery from SARM use. There are no controlled trials of SARM-cycle PCT efficacy. Recovery time after HPG-axis suppression is variable and not guaranteed.

pepSmart does not provide cycle planning or PCT planning for SARMs. The omission is intentional given the absence of clinical evidence and the regulatory posture above.

What the 'research only' label does not do

• It does not change FDA jurisdiction over the substance.
• It does not authorize sale of the substance for human use.
• It does not protect a buyer from a positive doping test.
• It does not protect a vendor from FDA enforcement or DOJ prosecution.
• It does not change state-level controlled-substance scheduling status.
• It does not change the WADA prohibited-list status.

Editorial summary

The most-studied SARM (MK-2866 / enobosarm) failed phase 3 for cancer cachexia. The next two most-discussed SARMs (LGD-4033, RAD-140) have only first-in-human or short-duration phase 1 data in healthy or oncology populations. None has FDA approval. All are WADA-prohibited at all times. Some are state-level controlled substances. Hepatotoxicity, HPG-axis suppression, and HDL reductions are documented at community body-composition doses. The 'research only' label is regulatory cosplay.